Table 1.
Pre-infection clinical and laboratory parameters in hematological patients affected by COVID-19 by baseline vaccination status.
| Pre-Infection Clinical and Laboratory Parameters | Fully Vaccinated (N = 34) |
Unvaccinated (N = 86) |
p-Value a,b |
|---|---|---|---|
| Median age, years (range) | 63 (30–94) | 65 (23–94) | 0.87 |
| Female gender, N (%) | 12 (35) | 43 (50) | 0.13 |
| Active and progressive disease, N (%) | 12 (35) | 27 (31) | 0.93 |
| Systemic treatment within 3 months, N (%) | 32 (94) | 45 (52) | <0.001 |
| ALC, ×103 cells/uL (range)) | 1.26 (0.4–188.0) | 1.5 (0.03–79.5) | 0.32 |
| ANC, ×103 cells/uL (range) | 3.7 (0.2–15.2) | 3.5 (0.0–22.1) | 0.98 |
| AMC, ×103 cells/uL (range) | 0.5 (0.1–2.1) | 0.4 (0.01–1.7 | 0.98 |
| LDH, IU/L (range) | 208 (92–980) | 201 (112–5000) | 0.97 |
| C-RP, IU/L (range) | 5 (1–157) | 2 (0–126) | 0.12 |
| Hematological malignancy type | |||
| Lymphoid neoplasm, N (%) | 8 (24) | 29 (34) | 0.38 |
| Myeloid neoplasm, N (%) | 6 (18) | 21 (24) | 0.48 |
| Plasma cell neoplasm, N (%) | 20 (59) | 36 (42) | 0.09 |
| Charlson comorbidity index 2 or more, N (%) | 16 (47) | 66 (75) | 0.003 |
| ECOG performance status 2 or more, N (%) | 10 (30) | 27 (31) | 0.92 |
a based on Fisher-exact test, b based on Mann–Whitney test. Abbreviations: ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; uL, micro-liter; IU/L, international units per liter; LDH, lactate de-hydrogenase; C-RP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group.